Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study

BackgroundThe oral, selective, and potent small molecule cyclin-dependent kinases (CDK) 4/6 inhibitor (CDK4/6i) abemaciclib has demonstrated efficacy in advanced breast cancer and high-risk early breast cancer. This Phase 1b study evaluated the safety, tolerability, pharmacokinetics, and antitumor a...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara M. Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L. Puhalla, Alison Conlin, E. Claire Dees, Muralidhar Beeram, Sonya C. Chapman, Andrew Lithio, Lacey M. Litchfield, Matthew P. Goetz
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Oncology
Subjects:
abemaciclib
metastatic breast cancer
CDK4
CDK6
everolimus
exemestane
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1555921/full

Similar Items